BD trades at $194.13 per share and has stayed right on track with the overall market, gaining 12.5% over the last six months. At the same time, the S&P 500 has returned 14.1%. Is now the time to buy ...

Becton, Dickinson and Company (NYSE:BDX) is included among the 15 Best Stocks to Buy for the Long Term. On December 2, Morgan Stanley analyst Patrick Wood lifted the firm’s price target on Becton, ...

Becton Dickinson (BDX) has quietly slipped this year, with the stock down about 16% year to date even as annual revenue and net income still show steady growth. This creates a potentially interesting ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Entering text into the input field will update the search result below ...

The latest price target for Becton Dickinson (NYSE:BDX) was reported by Morgan Stanley on December 2, 2025. The analyst firm set a price target for $210.00 expecting BDX to rise to within 12 months (a ...

Becton, Dickinson and Company (BDX) develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products. Valued at $55.4 billion by market cap, the company ...

About Xeris Biopharma Holdings Inc. Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has ...

This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It ...